Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: CYP2D6 polymorphisms and their influence on risperidone treatment
Authors: Apichaya Puangpetch
Natchaya Vanwong
Nopphadol Nuntamool
Yaowaluck Hongkaew
Monpat Chamnanphon
Chonlaphat Sukasem
Mahidol University
Keywords: Biochemistry, Genetics and Molecular Biology
Issue Date: 1-Dec-2016
Citation: Pharmacogenomics and Personalized Medicine. Vol.9, (2016), 131-147
Abstract: © 2016 Puangpetch et al. Cytochrome P450 enzyme especially CYP2D6 plays a major role in biotransformation. The interindividual variations of treatment response and toxicity are influenced by the polymorphisms of this enzyme. This review emphasizes the effect of CYP2D6 polymorphisms in risperidone treatment in terms of basic knowledge, pharmacogenetics, effectiveness, adverse events, and clinical practice. Although the previous studies showed different results, the effective responses in risperidone treatment depend on the CYP2D6 polymorphisms. Several studies suggested that CYP2D6 polymorphisms were associated with plasma concentration of risperidone, 9-hydroxyrisperidone, and active moiety but did not impact on clinical outcomes. In addition, CYP2D6 poor metabolizer showed more serious adverse events such as weight gain and prolactin than other predicted phenotype groups. The knowledge of pharmacogenomics of CYP2D6 in risperidone treatment is increasing, and it can be used for the development of personalized medication in term of genetic-based dose recommendation. Moreover, the effects of many factors in risperidone treatment are still being investigated. Both the CYP2D6 genotyping and therapeutic drug monitoring are the important steps to complement the genetic-based risperidone treatment.
ISSN: 11787066
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.